Why Appen, Breville, Credit Corp, and ResMed Shares Are Storming Higher Today
Why Appen, Breville, Credit Corp, and ResMed Shares Are Storming Higher Today
The $S&P/ASX 200 (.XJO.AU)$ has run out of steam and dropped into the red. In afternoon trade, the benchmark index is down a disappointing 0.5% to 7,953.2 points.
本基金寻求于东欧地区注册的主要权益关联发行人的长期升值投资。$S&P/ASX 200 (.XJO.AU)$指数已经失去支撑，走入下跌区间。在下午交易中，基准指数下跌了令人失望的0.5%，跌至7953.2点。
Four ASX shares that are not letting that hold them back today are listed below. Here's why they are rising:
以下四只ASX股票今日涨幅强劲，详情如下：
The Appen share price is up 23% to 53 cents. This follows the release of a quarterly update from the struggling artificial intelligence data services company this morning. Appen revealed that its revenue was down 16% on the prior corresponding period. However, this was due to the loss of Google as a customer. If you exclude Google, Appen's revenue would have been up 16% for the period. Management also reported improvements in its profitability and continues to target positive cash EBITDA during the second half of FY 2024.
Appen股价上涨23%，达到53美分。这是在今天早上这家陷入困境的人工智能数据服务公司发布季度更新之后发生的。Appen披露，其营业收入与去年同期相比下降了16%。然而，这是由于谷歌不再是客户。如果将谷歌排除在外，Appen的营业收入将在这一期间上涨16%。管理层还报告了其盈利能力的改善，并继续针对2024财年下半年实现正现金EBITDA。
The Breville Group share price is up 3.5% to $29.19. This is despite there being no news out of the appliance manufacturer on Tuesday. However, it is worth noting that analysts at Goldman Sachs reiterated their buy rating and $30.00 price target on Breville's shares yesterday. The broker commented: "We see 2H24 sales +9.3% YoY (+3% vs Factset) on first-time US sell-in to Target, improving HSD EMEA sales and -1% APAC from sluggish ANZ though strong S. Korea."
Breville Group股价上涨了3.5%，至29.19美元。这是尽管该电器制造商周二没有任何消息。然而，值得注意的是，高盛的分析师在昨天重申了对Breville股票的买入评级和30.00美元的价格目标。经纪人评论说：“我们预计2H24销售额同比增长9.3%（与Factset相比增长3%），首次销售至Target，欧中非高速增长，但因澳新寡淡而使亚太地区下降1%。”
The Credit Corp share price is up almost 7% to $16.22. Investors have been buying the debt collection company's shares today following the release of its FY 2024 results. Although Credit Corp posted a sizeable profit decline and slashed its dividend, the market appears to be focusing more on its guidance for FY 2025. The midpoint of its net profit after tax guidance range represents an increase of 17% on what was achieved in FY 2024.
Credit Corp股价上涨近7%，至16.22美元。今天，投资者正在购买这家催收公司的股票，这是因为该公司发布了2024财年的财报。尽管Credit Corp发布了大幅盈利下滑和削减股息，但市场似乎更关注其2025财年的指引。其净利润预期范围的中点相对于2024财年实现的利润增长了17%。
The ResMed share price is up almost 3% to $31.44. This follows a strong night of trade for the sleep disorder treatment company's shares on Wall Street. Investors were snapping up ResMed's shares on the belief that a selloff on Friday was an overreaction. As we covered here, the company's shares dropped after a medical device company with a similar customer base downgraded its revenue guidance. This sparked fears that weight loss drugs were having an impact. However, it seems that this downgrade was due to company specific issues and not because of Ozempic et all.
瑞思迈股价上涨近3%，至31.44美元。这是在睡眠障碍治疗公司的股票在华尔街表现强劲的一夜之后发生的。投资者正在抢购瑞思迈的股票，因为他们相信上周五的抛售行为是过度反应。正如我们在这里报道的那样，这家医疗器械公司由于类似的客户群体降低了其营收指引，导致其股票下跌。这激起人们对减肥药概念的担忧。然而，似乎这种降级是由于公司特定问题而不是由于欧塞普等药物引起的。